PGR (Progesterone Receptor) Drug Discovery Landscape & Assay Solutions
- By admin
- 20 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Breast Cancer, Endocrine Therapy, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PGR drug discovery, covering wild-type and key resistance mutants. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PGR Full-Length & LBD Recombinant Protein (Wild-type + H890Q/L881R Mutants) High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 Expressed. |
View PGR Products |
| Gene Delivery | PGR Lentivirus / Promise-ORF Plasmid Full-length ORF for stable cell line construction and reporter assays. |
View PGR Products |
| Benchmark Ab | Anti-PGR Monoclonal Antibody (Clone 636) Recombinant positive control for IHC/Western validation. |
View PGR Products |
| Validator | PGR siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View PGR Products |
| Pathway Partner (ESR1) | ESR1 (Estrogen Receptor α) Recombinant Protein Synergistic pathway target for HR+ breast cancer combination studies. |
View ESR1 Products |
| Subfamily Control (AR) | AR (Androgen Receptor) LBD Protein Selectivity screening control for nuclear receptor family cross-reactivity. |
View AR Products |
| Functional Partner (NCOA1) | NCOA1 (SRC1) Coactivator Protein For PPI and ternary complex assays. Endotoxin Controlled. |
View NCOA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Resistance Mutation Screening (H890Q, L881R) | Recombinant mutant proteins with verified amino acid substitutions, High Purity (>95%), Theoretical MW confirmed by Mass Spec |
| PROTAC Ternary Complex Validation | High-purity Ligand Binding Domain (LBD) proteins for SPR/BLI |
| Nuclear Receptor Selectivity | Homolog panel proteins (ESR1, AR, GR) strictly verified by mass spec |
| Lack of Controls / Benchmark Antibodies | Clinical Benchmark Antibodies included (Clone 636) |
| False Positives / Specificity Checks | Validated siRNA included for specificity checks |
Live PGR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PGR therapeutics is intensifying, with major players shifting focus from traditional Selective Progesterone Receptor Modulators (SPRMs) to Targeted Protein Degraders (PROTACs). As first-generation therapies reach the clinic for gynecological disorders and HR+ breast cancer, the next wave of R&D is targeting complete receptor degradation to overcome endocrine resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs / Degraders | Arvinas, Kymera | HR+ Breast Cancer | Ternary Complex Assay (Need high-purity LBD) |
| Small Molecule (SPRM) | Bayer, AbbVie | Endometriosis, Fibroids | Selectivity Assay (Need related NR proteins) |
| Bispecific / Combo | Pfizer, Novartis | Refractory Oncology | Resistance Modeling (Need Mutant vs WT Proteins) |